AT Bancorp lessened its holdings in shares of Edwards Lifesciences (NYSE:EW) by 29.9% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,856 shares of the medical research company’s stock after selling 8,896 shares during the quarter. AT Bancorp’s holdings in Edwards Lifesciences were worth $2,910,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also modified their holdings of the company. Cerebellum GP LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $128,000. Resources Investment Advisors Inc. lifted its position in shares of Edwards Lifesciences by 66.0% during the fourth quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock worth $132,000 after purchasing an additional 465 shares in the last quarter. Exane Derivatives lifted its position in shares of Edwards Lifesciences by 381.3% during the fourth quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock worth $137,000 after purchasing an additional 961 shares in the last quarter. Huber Financial Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the first quarter worth about $216,000. Finally, WESPAC Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the first quarter worth about $229,000. 83.02% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages recently weighed in on EW. Cowen reaffirmed a “buy” rating and issued a $165.00 target price on shares of Edwards Lifesciences in a report on Tuesday, March 20th. SunTrust Banks reaffirmed a “buy” rating and issued a $180.00 target price on shares of Edwards Lifesciences in a report on Tuesday, April 10th. Zacks Investment Research cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, April 4th. ValuEngine raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, May 7th. Finally, Northland Securities cut shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 25th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $148.53.
In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,800 shares of the stock in a transaction that occurred on Monday, April 30th. The shares were sold at an average price of $128.46, for a total value of $4,213,488.00. Following the transaction, the chief executive officer now directly owns 74,131 shares in the company, valued at $9,522,868.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $134.70, for a total transaction of $713,910.00. Following the completion of the transaction, the vice president now owns 24,908 shares in the company, valued at $3,355,107.60. The disclosure for this sale can be found here. Insiders sold 231,400 shares of company stock worth $31,473,269 over the last quarter. 1.84% of the stock is currently owned by insiders.
Shares of Edwards Lifesciences stock opened at $135.83 on Friday. The company has a market capitalization of $28.76 billion, a price-to-earnings ratio of 35.74, a P/E/G ratio of 2.01 and a beta of 0.64. Edwards Lifesciences has a 52 week low of $136.06 and a 52 week high of $137.15. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.63 and a current ratio of 2.07.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, April 24th. The medical research company reported $1.22 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.11 by $0.11. The company had revenue of $938.00 million for the quarter, compared to analyst estimates of $936.69 million. Edwards Lifesciences had a net margin of 17.36% and a return on equity of 28.60%. The firm’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.94 earnings per share. analysts anticipate that Edwards Lifesciences will post 4.61 EPS for the current fiscal year.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.